Shalata, W.; Weissmann, S.; Itzhaki Gabay, S.; Sheva, K.; Abu Saleh, O.; Jama, A.A.; Yakobson, A.; Rouvinov, K.
A Retrospective, Single-Institution Experience of Bullous Pemphigoid as an Adverse Effect of Immune Checkpoint Inhibitors. Cancers 2022, 14, 5451.
https://doi.org/10.3390/cancers14215451
AMA Style
Shalata W, Weissmann S, Itzhaki Gabay S, Sheva K, Abu Saleh O, Jama AA, Yakobson A, Rouvinov K.
A Retrospective, Single-Institution Experience of Bullous Pemphigoid as an Adverse Effect of Immune Checkpoint Inhibitors. Cancers. 2022; 14(21):5451.
https://doi.org/10.3390/cancers14215451
Chicago/Turabian Style
Shalata, Walid, Sarah Weissmann, Sapir Itzhaki Gabay, Kim Sheva, Omar Abu Saleh, Ashraf Abu Jama, Alexander Yakobson, and Keren Rouvinov.
2022. "A Retrospective, Single-Institution Experience of Bullous Pemphigoid as an Adverse Effect of Immune Checkpoint Inhibitors" Cancers 14, no. 21: 5451.
https://doi.org/10.3390/cancers14215451
APA Style
Shalata, W., Weissmann, S., Itzhaki Gabay, S., Sheva, K., Abu Saleh, O., Jama, A. A., Yakobson, A., & Rouvinov, K.
(2022). A Retrospective, Single-Institution Experience of Bullous Pemphigoid as an Adverse Effect of Immune Checkpoint Inhibitors. Cancers, 14(21), 5451.
https://doi.org/10.3390/cancers14215451